Clinical Trial

Remote Ischemic Preconditioning in Septic Patients

Study acronym: RIPC-ICU
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 12, 2024 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.
Summary
Acute kidney injury is a well-recognized complication in critically ill patients. Up to date there is no clinically established method to reduce the incidence or the severity of acute kidney injury. Remote ischemic preconditioning (RIPC) will be induced by three cycles of upper limb ischemia. The aim of the study is to reduce the incidence of AKI by implementing remote ischemic preconditioning (identified by the urinary biomarkers tissue inhibitor of metalloproteinases-2 (TIMP-2) and insulin-like growth factor-binding protein 7(IGFBP7)
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-04-13; most recent amendment 2024-12-06.
Status change: Not Yet Recruiting → Recruiting 2023-06-20
Trial Details
NCT Number NCT05830669
Lead Sponsor Universität Münster
Conditions Critically Ill, Acute Kidney Injury, Sepsis
Enrollment 64 participants
Start Date 2023-05-11
Primary Completion 2025-10 (estimated)
Study Completion 2026-01 (estimated)
Updated on ClinicalTrials.gov 2024-12-12